I've seen the presentation and I know the worldwide data on peptides targeting intracellular targets and the drugs in clinical trials and on the markets. Again, there was no data in the presentation showing that they could target an intracellular target with their peptides. The only data was on PYC35 and 36, which had to be linked to Tat protein (from HIV) to get them into cells, which no drug company will touch with a ten-foot pole. Tat has been around for years, and no peptide drug uses it. Looks good on paper, but it is meaningless. As far as your suggestion that they have additional comprehensive data on this, I'll point out that the drug industry has been looking for peptides that cross and disrupt intracellular protein-protein interactions for a long long time, and there are many companies doing it now, most looking at smaller peptides, compared to PYC's large sizes. If they really had such data, then why is none of the collaborations going after intracellular targets?? Roche is for a CPPs, Pfizer is for vaccines, and MedImmune for antibiotics, and Janssen is for CPPs. They are basically asking them to find alternatives to Tat and other well known CPP sequences that have proven failures clinically, Tat is not cell specific, whereas the phylomers may be able to do more cell specific CPPs, which could be very important and significant. CPPs are used to deliver payloads to cells and/or specific cell types (as carriers). They do not represent the functional part of the molecule. I hope you can appreciate the difference between CPPs and peptide drugs.
Management is never going to tell you when a collaboration ends. It is also their job to oversell the technology and its potential uses as much as possible. It is up to the shareholder to understand what is real and what is the real potential, and in biotech companies, that can be quite challenging.
I would venture to guess that all of BigPharma know about Phylogica and its technology. SO I will let PYC's revenue speak to what the technology can actually do compared to its competitors (and there are many).
PYC Price at posting:
2.4¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)